Panobacumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | Pseudomonas aeruginosa serotype IATS O11 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C38714H60189N10637O12187S322 |
| Molar mass | 879959.96 g·mol−1 |
| (what is this?) (verify) | |
Panobacumab (proposed INN) is a monoclonal antibody designed as an antibacterial against Pseudomonas aeruginosa.[1][2]
It is a fully human pentameric IgM antibody with a mouse J chain.[1]
Development
Panobacumab is being developed by Aridis Pharmaceuticals. As of November 15th it is in phase 2 clinical trials. The originator was Berna Biotech.[3]
The mechanism of action is as a lipopolysaccharide inhibitor.[3]
References
- ^ a b "Proposed INN: List 100 International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 22 (4). World Health Organization: 333. 2008.
- ^ Piscaglia M, Scaglione G, Genovese C, Borgonovo F, Brivio F, Rampichini F, Grifantini R, Bandera A, Gori A, Colaneri M, Palomba E (August 2025). "Exploring Human Use of Monoclonal Antibodies Against Critical Bacteria: A Scoping Review of Clinical Trials". Infectious Diseases and Therapy. 14 (8): 1619–1647. doi:10.1007/s40121-025-01195-2. PMC 12339841. PMID 40715971.
- ^ a b "Panobacumab - Aridis Pharmaceuticals". AdisInsight. Springer Nature Switzerland AG. Retrieved 15 November 2019.